Myriad Genetics, Inc. (MYGN) P/E Ratio History
Historical price-to-earnings valuation from 2008 to 2019
Loading P/E history...
MYGN Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Myriad Genetics, Inc. (MYGN) trades at a price-to-earnings ratio of -1.0x, with a stock price of $4.09 and trailing twelve-month earnings per share of $-4.27.
The current P/E is 102% below its 5-year average of 60.7x. Over the past five years, MYGN's P/E has ranged from a low of 15.2x to a high of 511.6x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, MYGN trades at a 105% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, MYGN trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our MYGN DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
MYGN P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $3B | 49.7 | - | +165% | |
| $21B | 25.5 | 6.01Best | +171%Best | |
| $21B | 24.7 | - | +18% | |
| $21B | 21.8Lowest | - | +14% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
MYGN Historical P/E Data (2008–2019)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2019 Q2 | Sun Jun 30 2019 00:00:00 GM | $27.78 | $0.05 | 511.6x | +1221% |
| FY2019 Q1 | Sun Mar 31 2019 00:00:00 GM | $33.20 | $0.29 | 114.3x | +195% |
| FY2018 Q4 | Mon Dec 31 2018 00:00:00 GM | $29.07 | $0.36 | 80.7x | +108% |
| FY2018 Q3 | Sun Sep 30 2018 00:00:00 GM | $46.00 | $0.78 | 58.9x | +52% |
| FY2018 Q2 | Sat Jun 30 2018 00:00:00 GM | $37.37 | $1.94 | 19.3x | -50% |
| FY2018 Q1 | Sat Mar 31 2018 00:00:00 GM | $29.55 | $1.95 | 15.2x | -61% |
| FY2017 Q4 | Sun Dec 31 2017 00:00:00 GM | $34.35 | $1.85 | 18.6x | -52% |
| FY2017 Q3 | Sat Sep 30 2017 00:00:00 GM | $36.18 | $1.49 | 24.3x | -37% |
| FY2017 Q2 | Fri Jun 30 2017 00:00:00 GM | $25.84 | $0.32 | 80.1x | +107% |
| FY2017 Q1 | Fri Mar 31 2017 00:00:00 GM | $19.20 | $0.45 | 42.4x | +10% |
| FY2016 Q4 | Sat Dec 31 2016 00:00:00 GM | $16.67 | $0.86 | 19.3x | -50% |
| FY2016 Q3 | Fri Sep 30 2016 00:00:00 GM | $20.58 | $1.18 | 17.4x | -55% |
Average P/E for displayed period: 38.7x
See MYGN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MYGN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MYGN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonMYGN — Frequently Asked Questions
Quick answers to the most common questions about buying MYGN stock.
Is MYGN stock overvalued or undervalued?
MYGN trades at -1.0x P/E, below its 5-year average of 60.7x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does MYGN's valuation compare to peers?
Myriad Genetics, Inc. P/E of -1.0x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is MYGN's PEG ratio?
MYGN PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2008-2019.